相似文献
1
Response to the letter titled "Targeting dementia prevention with semaglutide: the case for APOE4 homozygotes".
Alzheimers Dement. 2025 Jun;21(6):e70423. doi: 10.1002/alz.70423.
2
Targeting dementia prevention with semaglutide: The case for APOE4 homozygotes.
Alzheimers Dement. 2025 Jun;21(6):e70422. doi: 10.1002/alz.70422.
3
Multi-domain interventions for the prevention of dementia and cognitive decline.
Cochrane Database Syst Rev. 2021 Nov 8;11(11):CD013572. doi: 10.1002/14651858.CD013572.pub2.
4
Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.
Diabetes Obes Metab. 2025 Jun 19. doi: 10.1111/dom.16508.
5
homozygotes have less sleep fragmentation in late adulthood.
bioRxiv. 2025 Jun 2:2025.05.30.656615. doi: 10.1101/2025.05.30.656615.
6
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
7
Associations of semaglutide with Alzheimer's disease-related dementias in patients with type 2 diabetes: A real-world target trial emulation study.
J Alzheimers Dis. 2025 Jun 24:13872877251351329. doi: 10.1177/13872877251351329.
8
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
9
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Front Endocrinol (Lausanne). 2023 Aug 28;14:1244432. doi: 10.3389/fendo.2023.1244432. eCollection 2023.
10
Semaglutide in Adults with Type 1 Diabetes and Obesity.
NEJM Evid. 2025 Jun 23:EVIDoa2500173. doi: 10.1056/EVIDoa2500173.
本文引用的文献
1
Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the US.
Alzheimers Dement. 2024 Dec;20(12):8661-8672. doi: 10.1002/alz.14313. Epub 2024 Oct 24.
2
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission.
Lancet. 2024 Aug 10;404(10452):572-628. doi: 10.1016/S0140-6736(24)01296-0. Epub 2024 Jul 31.
3
Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes : Target Trial Emulation Using Real-World Data.
Ann Intern Med. 2024 Aug;177(8):1016-1027. doi: 10.7326/M23-2718. Epub 2024 Jul 30.
4
The benefits of GLP-1 drugs beyond obesity.
Science. 2024 Jul 19;385(6706):258-260. doi: 10.1126/science.adn4128. Epub 2024 Jul 18.
5
Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population.
Nat Commun. 2024 May 28;15(1):4548. doi: 10.1038/s41467-024-48780-6.
6
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
7
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
8
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.
Pharmacol Res. 2022 Aug;182:106320. doi: 10.1016/j.phrs.2022.106320. Epub 2022 Jun 20.
9
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.
10
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25.
Zotero 插件